04:05 PM EDT, 10/04/2024 (MT Newswires) -- Suitors for Sanofi's ( SNY ) consumer healthcare business Opella are making adjustments to their bids to tackle worries about possible legal issues associated with a brand that sold talcum powder, Bloomberg News reported Friday, citing people familiar with the matter.

Sanofi ( SNY ) requested potential buyers to update their offers for the healthcare division. The updated proposals might omit certain sections of the Gold Bond enterprise, which used to sell talc, or aim to avoid taking on any potential legal issues, according to the news outlet.

"Regarding Gold Bond, our medicated powders that historically contained talc were safe and asbestos-free," a Sanofi ( SNY ) spokesperson told MT Newswires. "Sanofi ( SNY ) relies on a history of high-quality sourcing, manufacturing, and scientific testing to support that its Gold Bond powders never contained asbestos. Any such claims, which have been previously disclosed, lack scientific support."

Revised bids may reportedly result in lower valuations and smaller debt packages. A transaction could put the asset at about 15 billion euros ($16.5 billion), the news outlet reported, citing people.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.

Price: 55.38, Change: -0.16, Percent Change: -0.29